The correlation between expression of synuclein-γ, glucose transporter-1, and survival outcomes in endometrioid endometrial carcinoma

Purpose: To evaluate the correlation between immunohistochemical expression of synuclein-γ, glucose transporter-1, and survival outcomes in endometrioid endometrial carcinoma. Materials and Methods: A tissue microarray was constructed using formalinfixed, paraffin-embedded tissue that included 23 early and 18 advanced cases. The intensity and area of the immunohistochemical reactions were evaluated using the semi-quantitative scoring system. Results: Synuclein-γ expression was higher in the advanced stage, although it was not statistically significant (p = 0.51). Glucose transporter-1 was overexpressed in the advanced stage (p = 0.01). Synuclein-γ (score = 0 vs > 0) and glucose transporter-1 (score ≤ 7 vs > 7) did not show any differences in overall survival (p = 0.54, p = 0.48) and disease-free survival (p = 0.61, p = 0.14). Conclusion: In this study the expression of synuclein-γ and glucose transporter-1 were not considered to be a prognostic factor and were not related with survival outcomes in endometrioid endometrial carcinoma.

Endometrial carcinoma; Synuclein-γ; Glucose transporter-1.

[1] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J.: “Cancer statistics”. C.A. Cancer J. Clin., 2009, 59, 225.

[2] Don S.: “Dizon; treatment options for advanced endometrial carcinoma”. Gynecol. Oncol., 2010, 117, 378.

[3] George J.M.: “The synucleins”. Genome Biol., 2002, 3, Reviews 3002. Epub 2001 Dec. 20.

[4] Lavedan C.: “The synuclein family”. Genome Res., 1998, 8, 871.

[5] Singh V.K., Zhou Y., Marsh J.A., Uversky V.N., Forman-Kay J.D., Liu J., Jia Z.: “Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs”. Cancer Res., 2007, 67, 626.

[6] Zhou Y., Inaba S., Liu J.: “Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment”. Int. J. Oncol., 2006, 29, 289.

[7] Airley R., Loncaster J., Davidson S., Bromley M., Roberts S., Patterson A. et al.: “Glucose transporter glucose transporter - 1 expression correlates with tumor hypoxia and predicts metastasisfree survival in advanced carcinoma of the cervix”. Clin. Cancer Res., 2001, 7, 928.

[8] Ito T., Noguchi Y., Satoh S., Hayashi H., Inayama Y., Kitamura H.: “Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage”. Mod. Pathol., 1998, 11, 437.

[9] Noguchi Y., Marat D., Saito A., Yoshikawa T., Doi C., Fukuzawa K. et al.: “Expression of facilitative glucose transporters in gastric tumors”. Hepatogastroenterology, 1999, 46, 2683.

[10] Haber R.S., Rathan A., Weiser K.R., Pritsker A., Itzkowitz S.H., Bodian C.S. et al.: “GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis”. Cancer, 1998, 83, 34.

[11] Bruening W., Giasson B.I., Klein-Szanto A.J., Lee V.M., Trojanowski J.Q., Godwin A.K.: “Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary”. Cancer, 2000, 88, 2154.

[12] Morgan J., Hoekstra A.V., Chapman-Davis E., Hardt J.L., Kim J.J., Buttin B.M.: “Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma”. Gynecol. Oncol., 2009, 114, 293.